Cell line · CVCL_2174
Papers36
1 to 20 of 36
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Intravenously deliverable oncolytic virus VET3-TGI favorably alters the tumor microenvironment. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CD40 agonism in renal cell carcinoma enhances immune checkpoint activity through myeloid cells. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| AQP1 Suppresses Clear Cell Renal Cell Carcinoma via Epigenetic Silencing and TNF-Mediated Apoptosis. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ICAM1high Neutrophils Sculpt Tumor Evolution and Metastasis Through Symbiotic Adhesion and Reverse Migration. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
An Integrated Immunometabolic Signature Predicts Prognosis and Immunotherapy Response in ccRCC and Identifies UCN-Mediated Immune Evasion as a Therapeutic Vulnerability: Evidence from In Vitro and In Vivo Studies. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T-Cell Infiltration and Limiting Myeloid Cell-Mediated Immunosuppression. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1-KDM5C-IL6 Axis in ccRCC. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Fe-S Protein FDX1 Triggers Tumor-Intrinsic Innate Immunity via Mitochondrial Nucleic Acids Release to Orchestrate Ferroptosis in CCRCC. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ERβ/circAHNAK Axis Inhibits USP10-FMR1 Deubiquitination to Prevent m⁶A-Mediated ADAM17 Decay and Promote Angiogenesis in Clear Cell Renal Cell Carcinoma. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the IL34-CSF1R axis improves metastatic renal cell carcinoma therapy outcome via immune-vascular crosstalk regulation. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape. | Elife | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting macrophage circadian rhythms with microcurrent stimulation to activate cancer immunity through phagocytic defense. | Theranostics | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Oncogenic accumulation of cysteine promotes cancer cell proliferation by regulating the translation of D-type cyclins. | J Biol Chem | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| VHL loss enhances antitumor immunity by activating the anti-viral DNA-sensing pathway. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CXCL3/TGF-β-mediated crosstalk between CAFs and tumor cells augments RCC progression and sunitinib resistance. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2174/papers